Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupThoracic TumorsDiseaseThymoma/Thymic CarcinomaSubgroupOctreotide Scintigraphy positiveICD10C37MeSHThymomaThymus NeoplasmsSequenceChemotherapyChemo-substanceCapecitabineCarboplatinCisplatinCyclophosphamideDoxorubicinEtoposideEverolimusGemcitabineIfosfamideMethylprednisoloneOctreotidePaclitaxelPembrolizumabPemetrexedSunitinibVincristineChemo-substanceCapecitabineCarboplatinCisplatinCyclophosphamideDoxorubicinEtoposideEverolimusGemcitabineIfosfamideMethylprednisoloneOctreotidePaclitaxelPembrolizumabPemetrexedSunitinibVincristineChemo-substanceCapecitabineCarboplatinCisplatinCyclophosphamideDoxorubicinEtoposideEverolimusGemcitabineIfosfamideMethylprednisoloneOctreotidePaclitaxelPembrolizumabPemetrexedSunitinibVincristineChemo-substanceCapecitabineCarboplatinCisplatinCyclophosphamideDoxorubicinEtoposideEverolimusGemcitabineIfosfamideMethylprednisoloneOctreotidePaclitaxelPembrolizumabPemetrexedSunitinibVincristineNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFilgrastimFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFilgrastimFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFilgrastimFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFilgrastimFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideNo. Substances124678Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleThird line Therapy phaseneoadjuvantTherapy intentioncurativepalliativeRisksAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlCardiotoxicityConstipationDiarrheaDyspneaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHand-Foot SyndromeHemorrhageHepatotoxicityHyperglycemiaHypertensionHypoalbuminemiaHypocalcemiaHypothyroidismIncrease AminotransferasesInfectionsLeukopeniaMucositisMyocarditisNeuropathyNeurotoxicityNeutropeniaOral MucositisPneumoniaPneumonitisPyrexiaRashRenal FailureThrombocytopenia below 50 000/µl only studiesPublicationAuthorBluthgen MV Cho JFornasiero AGbolahan OBGiaccone GKunitoh HLemma GLemma GLLoehrer, PJLoehrer PLoehrer PJPalmieri G Thomas AYokoi KZucali PADiseasefortgeschrittenes oder metastasiertes Thymuskarzinom, Erstlinie, ECOG 0-1Fortgeschrittenes oder metastasiertes Thymuskarzinom, Progress nach platinhaltiger Chemotherapie, ECOG 0-2fortgeschrittenes oder metastasiertes Thymuskarzinom oder Thymom, ECOG 0-2fortgeschrittenes Thymom bzw. Thymuskarzinom, ECOG 0-1Invasives Thymom Stadium III oder IVLokal fortgeschrittenes oder metastasiertes Thymom, ECOG 0-2lokal fortgeschrittenes oder metastasiertes Thymom, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Thymom, nach platinhaltiger TherapieLokal fortgeschrittenes oder metastasiertes Thymom/Thymuskarzinom, Progress nach platinbasierter Chemotherapie, ECOG 0-2Metastasiertes oder rezidiviertes Thymom, ECOG 0-2Thymom, Masaoka Stadium IVB, mindestens 2 Vortherapien, ECOG 0-1Thymom/Thymuskarzinom, lokal fortgeschritten oder metastasiert, vortherapiertThymom/Thymuskarzinom lokal fortgeschritten oder metastasiert, Octreotid-Szintigraphie positiv, ECOG 0-1Thymom in Masaoka Stadium IVa oder IVb, 15-70 Jahre, ECOG 0-2OriginDepartment of Cancer Medicine, Gustave Roussy, Villejuif, FranceDepartment of Medicine, Indiana University and the Walther Cancer Institute, IndianapolisDivisione di Oncologia Medica, PadovaEastern Cooperative Onkology Group, Southwest Oncology Group, Southeastern Cancer Study GroupEuropean Organisation für Research and Treatment of Cancer (EORTC), Lung Cancer Cooperative GroupHematology Oncology Division, Indiana University School of Medicine, Indianapolis, IndianaHumanitas Clinical and Research Center, Rozzano, Milan, ItalyIndiana University Medical Center and The Walther Cancer Institute, IndianapolisIndiana University Melvin and Bren Simon Cancer CenterIndiana University Melvin and Bren Simon Cancer Center, IndianapolisInha University School of Medicine, Incheon, South KoreaNational Cancer Center Hospital, Tokyo, Japan, JCOG 9605National Cancer Institute, National Institutes of Health, Bethesda, MD, USATochigi Cancer Center, Utsunomiya, Tochigi, JapanUniversity Federico II, Napoli, ItalyProtocols in Revision 15 protocols foundProtocols under revision.ADOC - Cisplatin 50 / Doxorubicin 40 / Vincristine 0.6 / Cyclophosphamide 700, Thymoma (PID369 V1.1)CAMP - Methylprednisolone (750/375) / Doxorubicin 40 / Cisplatin 20, Thymoma (PID1842 V1.1)CAP - Cisplatin 50 / Doxorubicin 50 / Cyclophosphamide 500, Thymoma (PID362 V1.1)CODE - Cisplatin 25 / Doxorubicin 40 / Etoposide 80 / Vincristine 1, Thymoma (PID1843 V1.1)Etoposide 25, Thymoma (PID2323 V1.0)Everolimus 10, Thymoma (PID1847 V1.0)Gemcitabine 1000 / Capecitabine 650, Thymoma (PID1844 V1.0)Octreotide 0.5, Thymoma (PID1845 V1.0)Paclitaxel 200 / Carboplatin 6, Thymic Carcinoma (PID1185 V1.1)Paclitaxel 225 / Carboplatin 6, Thymoma (PID363 V1.1)PE - Cisplatin 60 / Etoposide 120, Thymoma (PID368 V1.1)Pembrolizumab 200, Thymoma (PID2324 V1.0)Pemetrexed 500, Thymoma (PID1846 V1.0)Sunitinib 50, Thymic Carcinoma (PID2325 V1.0)VIP - Cisplatin 20 / Ifosfamide 1.2 / Etoposide 75, Thymoma (PID805 V1.2)
